Medullary thyroid cancer

Otolaryngologic Clinics of North America

Volumn 36, Issue 1, 2003, Pages 91-105

  Clayman, Gary L ^a   El Baradie, Tarek S ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; PROTEIN RET;

DECISION MAKING; DISEASE ACTIVITY; EARLY DIAGNOSIS; ENDOCRINOLOGY; FAMILIAL CANCER; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; MOLECULAR GENETICS; MULTIPLE ENDOCRINE NEOPLASIA; NECK TUMOR; NEUROFIBROMATOSIS; ONCOGENE RET; ONCOLOGY; PATHOLOGIST; PROGNOSIS; PROPHYLAXIS; PROTO ONCOGENE; RADIOLOGIST; RADIOTHERAPY; REVIEW; SIPPLE SYNDROME; SURGEON; THYROID MEDULLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROIDECTOMY;

CARCINOMA, MEDULLARY; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037302148     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0030-6665(02)00136-6     Document Type: Review

References (81)

1. Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997;79:564-73.
2. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2638-48.
3. Baloch ZW, LiVolsi VA. Neuroendocrine tumors of the thyroid gland. Am J Clin Pathol 2001;115(Suppl):S56-S67.
4. Burgess JR, Dwyer T, McArdle K, et al. The changing incidence and spectrum of thyroid carcinoma in Tasmania (1978-1998) during a transition from iodine sufficiency to iodine deficiency. J Clin Endocrinol Metab 2000;85:1513-7.
5. Hoie J, Jorgensen OG, Stenwig AE, et al. Medullary thyroid cancer in Norway. A 30-year experience. Acta Chir Scand 1988;154:339-43.
6. Lawal O, Agbakwuru A, Olayinka OS, et al. Thyroid malignancy in endemic nodular goitres: prevalence, pattern and treatment. Eur J Surg Oncol 2001;27:157-61.
7. Muthuphei MN. Carcinoma of the thyroid in Ga-Rankuwa Hospital, Pretoria. East Afr Med J 1999;76:700-2.
8. From G, Mellemgaard A, Knudsen N, et al. Review of thyroid cancer cases among patients with previous benign thyroid disorders. Thyroid 2000;10:697-700.
9. Alsanea O, Clark OH. Familial thyroid cancer. Curr Opin Oncol 2001;13:44-51.
10. Raue F. German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary thyroid carcinoma/multiple endocrine neoplasia Type 2. Langenbecks Arch Surg 1998;383:334-6.
11. Correa P, Chen VW. Endocrine gland cancer. Cancer 1995;75:338-52.
12. Bucsky P, Parlowsky T. Epidemiology and therapy of thyroid cancer in childhood and adolescence. Exp Clin Endocrinol Diabetes 1997;105(Suppl 4):70-3.
13. Stevenson JC. The structure and function of calcitonin. Invest cell path 1980;13:187-93.
14. Mosely JM, Mathews EW, Breed RH, et al. The ultimobranchial origin of calcitonin. Lancet 1968;I:108-10.
15. Wolfe HJ, Dellis RA, Volkel EF, et al. Distribution of calcitonin containing cells in adult human thyroid gland: a correlation of morphology with peptide content. J Clin Endocrinol Metab 1974;38:688-94.
16. Wolfe HJ, Dellis RA, Volkel EF, et al. Distribution of calcitonin containing cells in the normal and neonatal human thyroid gland: a correlation of morphology with peptide content. J Clin Endocrinol Metab 1975;41:1076-81.
17. Hoyes AD, Kershaw DR. Anatomy and development of the thyroid gland. Ear Nose Throat J 1985;64:318-33.
18. Wolfe HJ, Melvin KE, Cervi-Skinner SJ, et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med 1973;289:437-41.
19. Diaz-Cano SJ, de Miguel M, Blanes A, et al. Germline RET 634 mutation positive MEN 2A-related C-cell hyperplasias have genetic features consistent with intraepithelial neoplasia. J Clin Endocrinol Metab 2001;86:3948-57.
20. Perry A, Molberg K, Albores-Saavedra J. Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities. Cancer 1996;77: 750-6.
21. LiVolsi VA. Editorial: C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 1997;82:39-41.
22. Goretzki PE, Dotzenrath C, Simon D, et al. Studies of oncogenes and tumor-suppressor genes in human thyroid carcinomas, and their clinical implications. Langenbecks Arch Surg 1999;384:1-8.
23. Thakker RV. Multiple endocrine neoplasia. Horm Res 2001;56(Suppl 1):67-72.
24. Rosai J. Ackerman's surgical pathology. 8th edition. St. Louis: Mosby-Year Book, Inc.; 1996.
25. Dasovic-Knezevic M, Bormer O, Holm R, et al. Carcinoembryonic antigen in medullary thyroid carcinoma: an immunohistochemical study applying six novel monoclonal antibodies. Mod Pathol 1989;2:610-7.
26. Pacini F, Basolo F, Elisei R, et al. Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. Am J Clin Pathol 1991;95:300-8.
27. Uribe M, Fenoglio-Preiser CM, Grimes M, et al. Medullary carcinoma of the thyroid gland. Clinical, pathological, and immunohistochemical features with review of the literature. Am J Surg Pathol 1985;9:577-94.
28. Chong GC, Beahrs OH, Sizemore GW, et al. Medullary carcinoma of the thyroid gland. Cancer 1975;35:695-704.
29. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999;229:880-7.
30. Bergholm U, Adami HO, Bergstrom R, et al. Clinical characteristics in sporadic and familial medullary thyroid carcinoma. A nationwide study of 249 patients in Sweden from 1959 through 1981. Cancer 1989;63:1196-204.
31. Akerman M, Tennvall J, Biorklund A, et al. Sensitivity and specificity of fine needle aspiration cytology in the diagnosis of tumors of the thyroid gland. Acta Cytol 1985; 29:850-5.
32. Papaparaskeva K, Nagel H, Droese M. Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagn Cytopathol 2000;22:351-8.
33. DeLellis RA, Rule AH, Spiler I, et al. Calcitonin and carcinoembryonic antigen as tumor markers in medullary thyroid carcinoma. Am J Clin Pathol 1978;70:587-94.
34. Talerman A, Lindeman J, Kievit-Tyson PA, et al. Demonstration of calcitonin and carcinoembryonic antigen (CEA) in medullary carcinoma of the thyroid (MCT) by immunoperoxidase technique. Histopathology 1979;3:503-10.
35. Haber RS. Role of ultrasonography in the diagnosis and management of thyroid cancer. Endocr Pract 2000;6:396-400.
36. Koike A, Naruse T. Incidence of thyroid cancer in Japan. Semin Surg Oncol 1991;7: 107-111.
37. Lin JD, Huang BY, Weng HF, et al. Thyroid ultrasonography with fine-needle aspiration cytology for the diagnosis of thyroid cancer. J Clin Ultrasound 1997;25:111-8.
38. Wells SA Jr, Baylin SB, Leight GS, et al. The importance of early diagnosis in patients with hereditary medullary thyroid carcinoma. Ann Surg 1982;195:595-9.
39. Redding AH, Levine SN, Fowler MR. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid 2000;10:919-22.
40. Schmid KW, Ensinger C. "Atypical" medullary thyroid carcinoma with little or no calcitonin expression. Virchows Arch 1998;433:209-15.
41. Phay JE, Moley JF, Lairmore TC. Multiple endocrine neoplasias. Semin Surg Oncol 2000;18:324-32.
42. Pausova Z, Soliman E, Amizuka N, et al. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 1996;81:2711-8.
43. Nunziata V, Di Giovanni G, Lettera AM, et al. Cutaneous lichen amyloidosis associated with multiple endocrine neoplasia type 2A. Henry Ford Hosp Med J 1989;37: 144-6.
44. Pasini B, Rossi R, Ambrosio MR, et al. RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease. Surgery 2002;131:373-81.
45. Romeo G, Ceccherini I, Celli J, et al. Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. J Intern Med 1998;243:515-20.
46. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET protooncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996;276:1575-9.
47. Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995;267:381-3.
48. Hoff AO, Cote GJ, Gagel RF. Multiple endocrine neoplasias. Annu Rev Physiol 2000; 62:377-411.
49. Eng C, Smith DP, Mulligan LM, et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995;10:509-13.
50. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-6.
51. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET protooncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60.
52. Wohllk N, Cote GJ, Bugalho MM, et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996;81:3740-5.
53. Calmettes C, Ponder BA, Fischer JA, et al. Early diagnosis of the multiple endocrine neoplasia type 2 syndrome: consensus statement. European Community Concerted Action: Medullary Thyroid Carcinoma. Eur J Clin Invest 1992;22:755-60.
54. Simon S, Pavel M, Hensen J, et al. Multiple endocrine neoplasia 2A syndrome: surgical management. J Pediatr Surg 2002;37:897-900.
55. Sanso GE, Domene HM, Garcia R, et al. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer 2002; 94:323-30.
56. Evans DB, Fleming JB, Lee JE, et al. The surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol 1999;16:50-63.
57. Fleming JB, Lee JE, Bouvet M, et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 1999;230:697-707.
58. Weber T, Schilling T, Frank-Raue K, et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 2001;130:1044-9.
59. Dralle H, Damm I, Scheumann GF, et al. Frequency and significance of cervicomediastinal lymph node metastases in medullary thyroid carcinoma: results of a compartment-oriented microdissection method. Henry Ford Hosp Med J 1992;40:264-7.
60. Dralle H, Damm I, Scheumann GF, et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 1994;24:112-21.
61. Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000;88:1139-48.
62. Kraimps JL, Denizot A, Carnaille B, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d'Etude des Tumeurs a Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J Surg 1996;20:808-12.
63. Musholt TJ, Musholt PB, Behrend M, et al. Invasive differentiated thyroid carcinoma: tracheal resection and reconstruction procedures in the hands of the endocrine surgeon. Surgery 1999;126:1078-87.
64. Brierley J, Tsang R, Simpson WJ, et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996;6: 305-10.
65. Fife KM, Bower M, Harmer CL. Medullary thyroid cancer: the role of radiotherapy in local control. Eur J Surg Oncol 1996;22:588-91.
66. Plouin PF, Duclos JM, Soppelsa F, et al. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab 2001;86:1480-6.
67. Brauckhoff M, Gimm O, Brauckhoff K, et al. Calcitonin kinetics in the early postoperative period of medullary thyroid carcinoma. Langenbecks Arch Surg 2001;386:434-9.
68. Gimm O, Ukkat J, Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 1998;22: 562-67.
69. Moley JF, Dilley WG, DeBenedetti MK. Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 1997;225:734-40.
70. Yamazaki M, Zhang R, Straus FH, et al. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Ther 2002;9:64-74.
71. Parthasarathy R, Cote GJ, Gagel RF. Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res 1999;59:3911-4.
72. Mukherjee JJ, Kaltsas GA, Islam N, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine (131)I-mIBG. Clin Endocrinol (Oxf) 2001;55:47-60.
73. Troncone L, Rufini V, Maussier ML, et al. The possible use of radioiodinated metaiodobenzylguanidine (MIBG) in medullary thyroid carcinoma. Thyroidology 1988;Apr(1): 45-3.
74. Hyer SL, Vini L, A'Hern R, et al. Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol 2000;26:686-90.
75. Kakudo K, Carney JA, Sizemore GW. Medullary carcinoma of thyroid. Biologic behavior of the sporadic and familial neoplasm. Cancer 1985;55:2818-21.
76. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 1998;48:265-73.
77. Voutilainen PE, Multanen M, Haapiainen RK, et al. Long term prognosis of medullary thyroid carcinoma in 39 patients. Ann Chir Gynaecol 2000;89:292-7.
78. Bergholm U, Bergstrom R, Ekbom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 1997;79:132-8.
79. Cvejic D, Savin S, Golubovic S, et al. Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: possible relation to tumour progression. Histopathology 2000;37:530-5.
80. Schilling T, Burck J, Sinn HP, et al. Prognostic value of codon 918 (ATG→ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 2001; 95:62-6.
81. Zedenius J, Larsson C, Bergholm U, et al. Mutations of codon 918 in the RET protooncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 1995;80:3088-90.